BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

284 related articles for article (PubMed ID: 8658018)

  • 1. Soluble tumor necrosis factor receptors and CA 125 in serum as markers for epithelial ovarian cancer.
    Onsrud M; Shabana A; Austgulen R
    Tumour Biol; 1996; 17(2):90-6. PubMed ID: 8658018
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison between soluble tumor necrosis factor receptors and CA125 in peritoneal fluids as a marker for epithelial ovarian cancer.
    Onsrud M; Shabana A; Austgulen R; Nustad K
    Gynecol Oncol; 1995 May; 57(2):183-7. PubMed ID: 7729731
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differentiating stage 1 epithelial ovarian cancer from benign ovarian tumours using a combination of tumour markers HE4, CA125, and CEA and patient's age.
    Kondalsamy-Chennakesavan S; Hackethal A; Bowtell D; ; Obermair A
    Gynecol Oncol; 2013 Jun; 129(3):467-71. PubMed ID: 23500084
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tissue polypeptide-specific antigen and CA 125 as serum tumor markers in ovarian carcinoma.
    Shabana A; Onsrud M
    Tumour Biol; 1994; 15(6):361-7. PubMed ID: 7997808
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of soluble tumour necrosis factor alpha receptors p55 and p75 in ovarian cancer patients.
    Opala T; Rzymski P; Wilczak M; Woźniak J
    Eur J Gynaecol Oncol; 2005; 26(1):43-6. PubMed ID: 15754999
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical value of human epididymis protein 4 and the Risk of Ovarian Malignancy Algorithm in differentiating borderline pelvic tumors from epithelial ovarian cancer in early stages.
    Kotowicz B; Fuksiewicz M; Sobiczewski P; Spiewankiewicz B; Jonska-Gmyrek J; Skrzypczak M; Kowalska M
    Eur J Obstet Gynecol Reprod Biol; 2015 Nov; 194():141-6. PubMed ID: 26398337
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Proteomic biomarkers apolipoprotein A1, truncated transthyretin and connective tissue activating protein III enhance the sensitivity of CA125 for detecting early stage epithelial ovarian cancer.
    Clarke CH; Yip C; Badgwell D; Fung ET; Coombes KR; Zhang Z; Lu KH; Bast RC
    Gynecol Oncol; 2011 Sep; 122(3):548-53. PubMed ID: 21708402
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Clinical validation of multiple biomarkers suspension array technology for ovarian cancer].
    Zhao BB; Yang ZJ; Wang Q; Pan ZM; Zhang W; Li L
    Zhonghua Fu Chan Ke Za Zhi; 2017 Jan; 52(1):11-19. PubMed ID: 28190310
    [No Abstract]   [Full Text] [Related]  

  • 9. Serum tumor necrosis factor alpha receptors p55/p75 ratio and ovarian cancer detection.
    Rzymski P; Opala T; Wilczak M; Woźniak J; Sajdak S
    Int J Gynaecol Obstet; 2005 Mar; 88(3):292-8. PubMed ID: 15733884
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tissue CA125 and HE4 Gene Expression Levels Offer Superior Accuracy in Discriminating Benign from Malignant Pelvic Masses.
    Fawzy A; Mohamed MR; Ali MA; Abd El-Magied MH; Helal AM
    Asian Pac J Cancer Prev; 2016; 17(1):323-33. PubMed ID: 26838232
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association between serum levels of soluble tumor necrosis factor receptors/CA 125 and disease progression in patients with epithelial ovarian malignancy: a gynecologic oncology group study.
    Burger RA; Darcy KM; DiSaia PJ; Monk BJ; Grosen EA; Gatanaga T; Granger GA; Wang J; Tian C; Hanjani P; Cohn DE
    Cancer; 2004 Jul; 101(1):106-15. PubMed ID: 15221995
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New tumor markers: CA125 and beyond.
    Bast RC; Badgwell D; Lu Z; Marquez R; Rosen D; Liu J; Baggerly KA; Atkinson EN; Skates S; Zhang Z; Lokshin A; Menon U; Jacobs I; Lu K
    Int J Gynecol Cancer; 2005; 15 Suppl 3():274-81. PubMed ID: 16343244
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vascular endothelial growth factor (VEGF) improves the sensitivity of CA125 for differentiation of epithelial ovarian cancers from ovarian cysts.
    Robati M; Ghaderi A; Mehraban M; Shafizad A; Nasrolahi H; Mohammadianpanah M
    Arch Gynecol Obstet; 2013 Oct; 288(4):859-65. PubMed ID: 23564055
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Significance of preoperative serum CA-125 levels in the prediction of lymph node metastasis in epithelial ovarian cancer.
    Kim HS; Park NH; Chung HH; Kim JW; Song YS; Kang SB
    Acta Obstet Gynecol Scand; 2008; 87(11):1136-42. PubMed ID: 18951217
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of plasma amino acid profile-based index and CA125 in the diagnosis of epithelial ovarian cancers and borderline malignant tumors.
    Miyagi E; Maruyama Y; Mogami T; Numazaki R; Ikeda A; Yamamoto H; Hirahara F
    Int J Clin Oncol; 2017 Feb; 22(1):118-125. PubMed ID: 27623814
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of HE4, CA125, risk of ovarian malignancy algorithm (ROMA) and risk of malignancy index (RMI) as diagnostic tools of epithelial ovarian cancer in patients with a pelvic mass.
    Karlsen MA; Sandhu N; Høgdall C; Christensen IJ; Nedergaard L; Lundvall L; Engelholm SA; Pedersen AT; Hartwell D; Lydolph M; Laursen IA; Høgdall EV
    Gynecol Oncol; 2012 Nov; 127(2):379-83. PubMed ID: 22835718
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HE4, CA125, the Risk of Malignancy Algorithm and the Risk of Malignancy Index and complex pelvic masses - a prospective comparison in the pre-operative evaluation of pelvic masses in an Australian population.
    Richards A; Herbst U; Manalang J; Pather S; Saidi S; Tejada-Berges T; Tan K; Williams P; Carter J
    Aust N Z J Obstet Gynaecol; 2015 Oct; 55(5):493-7. PubMed ID: 26172511
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of HE4, CA125, and Risk of Ovarian Malignancy Algorithm in the Prediction of Ovarian Cancer in Korean Women.
    Cho HY; Park SH; Park YH; Kim HB; Kang JB; Hong SH; Kyung MS
    J Korean Med Sci; 2015 Dec; 30(12):1777-83. PubMed ID: 26713052
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Diagnostic performance of the biomarkers HE4 and CA125 in type I and type II epithelial ovarian cancer.
    Kristjansdottir B; Levan K; Partheen K; Sundfeldt K
    Gynecol Oncol; 2013 Oct; 131(1):52-8. PubMed ID: 23891789
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Diagnostic Model of Serum miR-193a-5p, HE4 and CA125 Improves the Diagnostic Efficacy of Epithelium Ovarian Cancer.
    Ren X; Zhang H; Cong H; Wang X; Ni H; Shen X; Ju S
    Pathol Oncol Res; 2018 Oct; 24(4):739-744. PubMed ID: 29520570
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.